Hologic's Q3FY12 prelims promise to please investors, while $3.7bn Gen-Probe buy makes tracks
This article was originally published in Clinica
Investors in Hologic should not have to worry about receiving bad news from the women's health company this earnings season after the company confirmed that its fiscal third quarter profits will meet, or even exceed, the guidance it had set in April.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.